Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04387461
Title Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin (Core-001)
Acronym CORE-001
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors CG Oncology, Inc.
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.